Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus to change supplier, aims to be more price competitive

A strategic review recently identified the need to be more price competitive.
drip in a patient's arm
Go Medical supplied smaller intravenous consumable medical products

Admedus Ltd (ASX:AHZ) and supplier Go Medical Industries Pty Ltd have concluded their relationship.

Go Medical is a manufacturer of medical devices and accessories for the company’s Infusion business.

Admedus’s CEO Wayne Paterson said: “The company believes that this outcome is in the best interest of all stakeholders in the short, medium, and long-term.

READ: Admedus raises $2.76 million from share purchase plan

“While this may have a short-term impact on the timing of breakeven earnings, the company still aims to be profitable for 2019.

“We have a great team in place who consistently deliver above-target sales revenue and offer premium service to our valued customers.”

Adequate supply to meet near-term demand

Admedus is committed to working closely with existing customers and Go Medical as it transitions the business, and confirms it has adequate supply to meet demand during the 45-day completion period.

This change in the supplier arrangement is expected to have a 5.7% impact on top-line revenue for the financial year.

It is important to note that this change relates only to the supply of smaller intravenous consumable medical products, and has no impact on Admedus’ distribution of infusion pumps to major hospitals.

Admedus making changes to be more competitive

Under the leadership of its new business unit head, Glenn Gilchrist, Admedus has been refreshing its long-term strategic plan for the Infusion business.

This includes assessing its capabilities, organisational footprint, and product portfolio.

The review identified certain products and pricing within the portfolio which needed to be more competitive.

Admedus engaged Go Medical on these topics, seeking a mutually beneficial outcome, but unfortunately were unable to reach agreement.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

Respiratory syncytial virus causes the common cold, for which there is no effective cure.
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use